The response of uterine fibroids to GnRH-agonist treatment can be predicted in most cases after one month
- 1 July 1992
- journal article
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 45 (2) , 125-129
- https://doi.org/10.1016/0028-2243(92)90228-q
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomasAmerican Journal of Obstetrics and Gynecology, 1991
- Clinical predictors for buserelin acetate treatment of uterine fibroids: a prospective study of 40 womenFertility and Sterility, 1990
- Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: The estrogen threshold hypothesisAmerican Journal of Obstetrics and Gynecology, 1990
- Präoperative Reduktion von Uterusmyomen durch das GnRH-Analogon Goserelin (Zoladex®)Geburtshilfe und Frauenheilkunde, 1990
- A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomataFertility and Sterility, 1989
- Treatment of leiomyomata uteri with D-Trp6-luteinizing hormone-releasing hormoneFertility and Sterility, 1987
- SUPPRESSION OF OVARIAN ACTIVITY BY ZOLADEX DEPOT (ICI 118630), A LONG‐ACTING LUTEINIZING HORMONE RELEASING HORMONE AGONIST ANALOGUEClinical Endocrinology, 1987
- Endocrine effects of goserelin, a new depot luteinising hormone releasing hormone agonist.BMJ, 1986
- A conservative approach to the management of uterine leiomyoma: Pituitary desensitization by a luteinizing hormone-releasing hormone analogueAmerican Journal of Obstetrics and Gynecology, 1983
- Uterine leiomyomata: etiology, symptomatology, and managementFertility and Sterility, 1981